Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer

Objective There is no consensus on whether platinum doublet chemotherapy or lenvatinib and pembrolizumab (LEN/PEM) is superior for advanced or recurrent endometrial cancer. Thus, this study aimed to compare the prognosis and adverse events in patients with advanced or recurrent endometrial cancer tr...

Full description

Saved in:
Bibliographic Details
Main Authors: Yutaka Yoneoka (Author), Tsukuru Amano (Author), Akimasa Takahashi (Author), Hiroki Nishimura (Author), Mari Deguchi (Author), Hiroyuki Yamanaka (Author), Yuji Tanaka (Author), Shunichiro Tsuji (Author), Takashi Murakami (Author)
Format: Book
Published: Korean Society of Obstetrics and Gynecology, 2024-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available